TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8

Approval Year

Substance Class	Protein
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	4K108E14CS
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY MEMBER 8

Common Name

English

LYMPHOCYTE ACTIVATION ANTIGEN CD30

Common Name

English

D1S166E

Common Name

English

KI-1 ANTIGEN

Common Name

English

CD-30

Common Name

English

Showing 1 to 5 of 6 entries

Previous1 2Next

Show entries

Code System

Code

Type

Description

PHAROS

P28908

PRIMARY

UNIPROT

P28908

PRIMARY

FDA UNII

4K108E14CS

PRIMARY

Showing 1 to 3 of 3 entries

Previous1Next

Subunit 0

Show entries

From	To
1_11	1_26
1_27	1_40
1_30	1_47
1_51	1_63
1_66	1_80

Showing 1 to 5 of 14 entries

Previous1 2 3Next

Glycosylation Type

HUMAN

Show entries

Glycosylation Link Type	Site
N	1_83
N	1_258

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					7XL5ISS668

BRENTUXIMAB VEDOTIN

CONJUGATED TOXIN->TARGET


					33VWC847G8

XMAB-2513

LIGAND->TARGET

Comments:

Anti-CD30 monoclonal antibody XmAb2513 specifically binds to the CD30 antigen, which may result in a cytotoxic T lymphocyte (CTL) response against CD30-expressing tumor cells.


					AYH22O1B1U

IRATUMUMAB

LIGAND->TARGET


					7XL5ISS668

BRENTUXIMAB VEDOTIN

INHIBITOR -> TARGET


					ND470TT8Y3

Acimtamig

LIGAND->TARGET

Comments:

Determined by Surface Plasmon Resonance (SPR).

Amount:

1.3 NANOMOLAR (average)

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL

Showing 1 to 1 of 1 entries

Previous1Next